Literature DB >> 25159209

Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.

Joshua M Barnett1, Sandra Suarez2, Gary W McCollum3, John S Penn1.   

Abstract

PURPOSE: We investigated endoglin expression in hypoxic microvascular endothelial cells and retinal endoglin expression in rats that develop experimental oxygen-induced retinopathy (OIR). We also tested neutralizing antibodies (Abs) against endoglin (anti-CD105 Ab) and VEGF (anti-VEGF Ab) either alone or in combination for efficacy against serum-induced retinal microvascular endothelial cell proliferation and retinal neovascularization (NV) in OIR rats. To our knowledge, this marks the first time that a biologic agent has been used to target retinal endoglin and modulate retinal neovascularization.
METHODS: Induction of endoglin by hypoxia was measured by immunohistochemical analysis and ELISA. Proliferation was quantified using a colorimetric 5-bromo-2-deoxyuridine ELISA. Western blots were used to measure endoglin levels in retinas of OIR rats. Immunohistochemical staining was also preformed in OIR rats using anti-CD105 and fluorescein isothiocyanate-conjugated isolectin B4 antibodies.
RESULTS: Anti-CD105 Ab and Anti-VEGF Ab, administered alone or in combination, reduced serum-induced retinal microvascular endothelial cell proliferation. Additionally, in a rat model of oxygen-induced retinopathy, retinal endoglin was significantly increased at 14(2), 14(3), 14(4) and 14(6) compared with retinal levels in control rats. At 14(2), immunohistochemical analysis demonstrated that endoglin was elevated in newly developed vessels at the peripheral extent of major veins, precisely where NV is expected to develop in OIR rats. Neutralizing anti-CD105 reduced retinal NV in OIR rats.
CONCLUSIONS: Our data support other studies showing that reduction of endoglin expression inhibits retinal NV. Our findings demonstrate that retinal endoglin immunolocalization overlaps with nascent neovascular structures in OIR rats. Therefore, endoglin may serve as a useful predictor of incipient neovascular disease. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  angiogenesis; early diagnostic biomarker; retinal neovascularization

Mesh:

Substances:

Year:  2014        PMID: 25159209      PMCID: PMC4197712          DOI: 10.1167/iovs.14-14945

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  61 in total

1.  From the Centers for Disease Control and Prevention. Blindness caused by diabetes--Massachusetts, 1987-1994.

Authors: 
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

2.  Role of cytosolic phospholipase A(2) in retinal neovascularization.

Authors:  Joshua M Barnett; Gary W McCollum; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

3.  Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy.

Authors:  Tom A Gardiner; David S Gibson; Tanyth E de Gooyer; Vidal F de la Cruz; Denise M McDonald; Alan W Stitt
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 4.  Angiogenesis research: guidelines for translation to clinical application.

Authors:  J Folkman; T Browder; J Palmblad
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

Review 5.  Retinopathy of prematurity.

Authors:  Jing Chen; Lois E H Smith
Journal:  Angiogenesis       Date:  2007-02-27       Impact factor: 9.596

6.  Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.

Authors:  Luis Arias; Jose M Caminal; Maria B Badia; Marcos J Rubio; Jaume Catala; Octavio Pujol
Journal:  Retina       Date:  2010 Nov-Dec       Impact factor: 4.256

7.  Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily.

Authors:  N P Barbara; J L Wrana; M Letarte
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis.

Authors:  Zhen Liu; Franck Lebrin; Janita A Maring; Sander van den Driesche; Stieneke van der Brink; Maarten van Dinther; Midory Thorikay; Sabrina Martin; Kazuki Kobayashi; Lukas J A C Hawinkels; Laurens A van Meeteren; Evangelia Pardali; Jeroen Korving; Michelle Letarte; Helen M Arthur; Charles Theuer; Marie-José Goumans; Christine Mummery; Peter ten Dijke
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Authors:  Yingmiao Liu; Hongyu Tian; Gerard C Blobe; Charles P Theuer; Herbert I Hurwitz; Andrew B Nixon
Journal:  Invest New Drugs       Date:  2014-07-05       Impact factor: 3.850

View more
  9 in total

1.  Dilated microvessel with endothelial cell proliferation involves intraplaque hemorrhage in unstable carotid plaque.

Authors:  Daina Kashiwazaki; Shusuke Yamamoto; Naoki Akioka; Emiko Hori; Takashi Shibata; Naoya Kuwayama; Kyo Noguchi; Satoshi Kuroda
Journal:  Acta Neurochir (Wien)       Date:  2020-09-30       Impact factor: 2.216

2.  miR-342-5p Is a Notch Downstream Molecule and Regulates Multiple Angiogenic Pathways Including Notch, Vascular Endothelial Growth Factor and Transforming Growth Factor β Signaling.

Authors:  Xian-Chun Yan; Jing Cao; Liang Liang; Li Wang; Fang Gao; Zi-Yan Yang; Juan-Li Duan; Tian-Fang Chang; San-Ming Deng; Yuan Liu; Guo-Rui Dou; Jian Zhang; Qi-Jun Zheng; Ping Zhang; Hua Han
Journal:  J Am Heart Assoc       Date:  2016-02-08       Impact factor: 5.501

Review 3.  A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases.

Authors:  Ashley Stark; Christiane Dammann; Heber C Nielsen; MaryAnn V Volpe
Journal:  Front Pediatr       Date:  2018-06-13       Impact factor: 3.418

4.  Ocular macrophage origin and heterogeneity during steady state and experimental choroidal neovascularization.

Authors:  Steven Droho; Benjamin R Thomson; Hadijat M Makinde; Carla M Cuda; Harris Perlman; Jeremy A Lavine
Journal:  J Neuroinflammation       Date:  2020-11-13       Impact factor: 8.322

5.  Syndecan-3 regulates MSC adhesion, ERK and AKT signalling in vitro and its deletion enhances MSC efficacy in a model of inflammatory arthritis in vivo.

Authors:  Fiona K Jones; Andrei Stefan; Alasdair G Kay; Mairead Hyland; Rebecca Morgan; Nicholas R Forsyth; Addolorata Pisconti; Oksana Kehoe
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.379

6.  A novel method for visualizing and tracking endogenous mRNA in a specific cell population in pathological neovascularization.

Authors:  Md Imam Uddin; Tyler C Kilburn; Sara Z Jamal; Craig L Duvall; John S Penn
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

7.  Ly6c as a New Marker of Mouse Blood Vessels: Qualitative and Quantitative Analyses on Intact and Ischemic Retinas.

Authors:  Marina Martínez-Carmona; Fernando Lucas-Ruiz; Alejandro Gallego-Ortega; Caridad Galindo-Romero; María Norte-Muñoz; María José González-Riquelme; Francisco J Valiente-Soriano; Manuel Vidal-Sanz; Marta Agudo-Barriuso
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

8.  Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis.

Authors:  Claudia Ollauri-Ibáñez; Elena Núñez-Gómez; Cristina Egido-Turrión; Laura Silva-Sousa; Elena Díaz-Rodríguez; Alicia Rodríguez-Barbero; José M López-Novoa; Miguel Pericacho
Journal:  Angiogenesis       Date:  2020-01-03       Impact factor: 9.596

Review 9.  Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?

Authors:  Claudia Ollauri-Ibáñez; Blanca Ayuso-Íñigo; Miguel Pericacho
Journal:  Cancers (Basel)       Date:  2021-03-28       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.